Nemolizumab

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Mon Mar 31 22:39:21 GMT 2025` Edited by `admin` on `Mon Mar 31 22:39:21 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG2
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	GN465U8B72
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

CIM-331

Preferred Name

English

Nemolizumab

Official Name

English

NEMOLIZUMAB [USAN]

Common Name

English

immunoglobulin G2-kappa, anti-[Homo sapiens IL31RA (interleukin 31 receptor subunit alpha)], humanized monoclonal antibody gamma2 heavy chain (1-445) [humanized VH (Homo sapiens IGHV1-2*02 (83.70%) -(IGHD)-IGHJ5*01) [8.8.14] (1-121) -Homo sapiens IGHG2*0

Common Name

English

NEMOLIZUMAB [JAN]

Common Name

English

Immunoglobulin G2, anti-(interleukin 31 receptor A) (human-Mus musculus monoclonal CIM331 ?-chain), disulfide with human-Mus musculus monoclonal CIM331 ?-chain, dimer

Common Name

English

nemolizumab [INN]

Common Name

English

CIM331

Code

English

Nemolizumab [WHO-DD]

Common Name

English

Code System Code Type Description

CAS

1476039-58-3

Created by admin on Mon Mar 31 22:39:21 GMT 2025 , Edited by admin on Mon Mar 31 22:39:21 GMT 2025

PRIMARY

FDA UNII

GN465U8B72

Created by admin on Mon Mar 31 22:39:21 GMT 2025 , Edited by admin on Mon Mar 31 22:39:21 GMT 2025

PRIMARY

SMS_ID

100000176257

Created by admin on Mon Mar 31 22:39:21 GMT 2025 , Edited by admin on Mon Mar 31 22:39:21 GMT 2025

PRIMARY

WIKIPEDIA

Nemolizumab

Created by admin on Mon Mar 31 22:39:21 GMT 2025 , Edited by admin on Mon Mar 31 22:39:21 GMT 2025

PRIMARY

DRUG BANK

DB15252

Created by admin on Mon Mar 31 22:39:21 GMT 2025 , Edited by admin on Mon Mar 31 22:39:21 GMT 2025

PRIMARY

INN

10064

Created by admin on Mon Mar 31 22:39:21 GMT 2025 , Edited by admin on Mon Mar 31 22:39:21 GMT 2025

PRIMARY

USAN

LM-25

Created by admin on Mon Mar 31 22:39:21 GMT 2025 , Edited by admin on Mon Mar 31 22:39:21 GMT 2025

PRIMARY

NCI_THESAURUS

C170211

Created by admin on Mon Mar 31 22:39:21 GMT 2025 , Edited by admin on Mon Mar 31 22:39:21 GMT 2025

PRIMARY

From	To
1_22	1_96
1_148	1_204
1_261	1_321
1_367	1_425
2_22	2_96
2_148	2_204
2_261	2_321
2_367	2_425
3_23	3_88
3_134	3_194
4_23	4_88
4_134	4_194
1_224	3_214
2_224	4_214
1_227	2_227
1_230	2_230

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_297
N	2_297

Related Record Type Details

Nemolizumab-ILTO

SUB_CONCEPT->SUBSTANCE

Amount:


					3JW47OGM6P

INTERLEUKIN-3 RECEPTOR SUBUNIT ALPHA

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					GN465U8B72

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS			PIDOLIC ACID	SZB83O1W42

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL